We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ACADIA Starts Phase II Schizophrenia Study on Pimavanserin
Read MoreHide Full Article
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) announced the initiation of a phase II study; ADVANCE, to evaluate pimavanserin for treating patients with negative symptoms of schizophrenia.
ADVANCE is a randomized, double-blind, placebo-controlled, and multi-center study designed for examining the efficacy and safety of adjunctive use of pimavanserin in treating the above patient group.
Pimavanserin is already approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis under the trade name Nuplazid. Nuplazid was commercially launched in May this year.
According to the company’s press reelase, 40–50% of patients suffering from schizophrenia have prominent negative symptoms. Currently no drug is approved by the FDA for the treatment of these symptoms. Pimavanserin is selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors.
Meanwhile, the company is forging ahead with its multi-year plans of developing pimavanserin in indications beyond Parkinson’s disease psychosis. The company has completed enrollment in a phase II exploratory study on pimavanserin for the treatment of Alzheimer’s disease. Top-line results from this study are expected to be announced by the end of 2016.
ACADIA currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Arbutus Biopharma Corporation (ABUS - Free Report) , Heska Corporation and Anika Therapeutics Inc. (ANIK - Free Report) . Anika and Heska sport a Zacks Rank #1 (Strong Buy) while Arbutus carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Arbutus’ loss estimates narrowed from $2.15 to $1.77 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.
Heska’s earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters, with an average beat of 301.64%.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters, with an average beat of 33.14%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
ACADIA Starts Phase II Schizophrenia Study on Pimavanserin
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) announced the initiation of a phase II study; ADVANCE, to evaluate pimavanserin for treating patients with negative symptoms of schizophrenia.
ADVANCE is a randomized, double-blind, placebo-controlled, and multi-center study designed for examining the efficacy and safety of adjunctive use of pimavanserin in treating the above patient group.
Pimavanserin is already approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis under the trade name Nuplazid. Nuplazid was commercially launched in May this year.
According to the company’s press reelase, 40–50% of patients suffering from schizophrenia have prominent negative symptoms. Currently no drug is approved by the FDA for the treatment of these symptoms. Pimavanserin is selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors.
Meanwhile, the company is forging ahead with its multi-year plans of developing pimavanserin in indications beyond Parkinson’s disease psychosis. The company has completed enrollment in a phase II exploratory study on pimavanserin for the treatment of Alzheimer’s disease. Top-line results from this study are expected to be announced by the end of 2016.
ACADIA PHARMA Price
ACADIA PHARMA Price | ACADIA PHARMA Quote
ACADIA currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Arbutus Biopharma Corporation (ABUS - Free Report) , Heska Corporation and Anika Therapeutics Inc. (ANIK - Free Report) . Anika and Heska sport a Zacks Rank #1 (Strong Buy) while Arbutus carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Arbutus’ loss estimates narrowed from $2.15 to $1.77 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.
Heska’s earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters, with an average beat of 301.64%.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters, with an average beat of 33.14%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>